Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308834504> ?p ?o ?g. }
- W4308834504 endingPage "252" @default.
- W4308834504 startingPage "242" @default.
- W4308834504 abstract "To assess the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in a phase II trial in adult patients with active systemic lupus erythematosus (SLE).Adults with active SLE were enrolled from 162 sites in 17 countries. Patients (n = 363) were randomized 1:1:1:1 to receive deucravacitinib 3 mg twice daily, 6 mg twice daily, 12 mg once daily, or placebo. The primary end point was SLE Responder Index 4 (SRI-4) response at week 32. Secondary outcomes assessed at week 48 included SRI-4, British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response, Cutaneous Lupus Erythematosus Disease Area and Severity Index 50 (CLASI-50), Lupus Low Disease Activity State (LLDAS), and improvements in active (swollen plus tender), swollen, and tender joint counts.At week 32, the percentage of patients achieving SRI-4 response was 34% with placebo compared to 58% with deucravacitinib 3 mg twice daily (odds ratio [OR] 2.8 [95% confidence interval (95% CI) 1.5, 5.1]; P < 0.001 versus placebo), 50% with 6 mg twice daily (OR 1.9 [95% CI 1.0, 3.4]; P = 0.02 versus placebo), and 45% with 12 mg once daily (OR 1.6 [95% CI 0.8, 2.9]; nominal P = 0.08 versus placebo). Response rates were higher with deucravacitinib treatment for BICLA, CLASI-50, LLDAS, and joint counts compared to placebo. Rates of adverse events were similar across groups, except higher rates of infections and cutaneous events, including rash and acne, with deucravacitinib treatment. Rates of serious adverse events were comparable, with no deaths, opportunistic infections, tuberculosis infections, major adverse cardiovascular events, or thrombotic events reported.Deucravacitinib treatment elicited higher response rates for SRI-4 and other end points compared with placebo, with an acceptable safety profile, in adult patients with active SLE." @default.
- W4308834504 created "2022-11-17" @default.
- W4308834504 creator A5004760940 @default.
- W4308834504 creator A5008572529 @default.
- W4308834504 creator A5018812946 @default.
- W4308834504 creator A5022135220 @default.
- W4308834504 creator A5023265561 @default.
- W4308834504 creator A5029793095 @default.
- W4308834504 creator A5033195023 @default.
- W4308834504 creator A5034905722 @default.
- W4308834504 creator A5036855659 @default.
- W4308834504 creator A5052053321 @default.
- W4308834504 creator A5052310815 @default.
- W4308834504 creator A5062998292 @default.
- W4308834504 creator A5083502971 @default.
- W4308834504 date "2022-11-11" @default.
- W4308834504 modified "2023-10-13" @default.
- W4308834504 title "Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp> , Randomized, <scp>Double‐Blind</scp> , <scp>Placebo‐Controlled</scp> Trial" @default.
- W4308834504 cites W2046330020 @default.
- W4308834504 cites W2058603733 @default.
- W4308834504 cites W2069498935 @default.
- W4308834504 cites W2091468965 @default.
- W4308834504 cites W2110793425 @default.
- W4308834504 cites W2111416025 @default.
- W4308834504 cites W2136149088 @default.
- W4308834504 cites W2139198208 @default.
- W4308834504 cites W2159860161 @default.
- W4308834504 cites W2168146874 @default.
- W4308834504 cites W2199189793 @default.
- W4308834504 cites W2480131152 @default.
- W4308834504 cites W2486559230 @default.
- W4308834504 cites W2593565645 @default.
- W4308834504 cites W2599738383 @default.
- W4308834504 cites W2704151968 @default.
- W4308834504 cites W2766830060 @default.
- W4308834504 cites W2767352498 @default.
- W4308834504 cites W2775607224 @default.
- W4308834504 cites W2892136519 @default.
- W4308834504 cites W2918490681 @default.
- W4308834504 cites W2921490251 @default.
- W4308834504 cites W2964002548 @default.
- W4308834504 cites W2983004004 @default.
- W4308834504 cites W2995521654 @default.
- W4308834504 cites W3029018600 @default.
- W4308834504 cites W3041234419 @default.
- W4308834504 cites W3165895944 @default.
- W4308834504 cites W4210435204 @default.
- W4308834504 cites W4214874713 @default.
- W4308834504 cites W4220949630 @default.
- W4308834504 cites W4280627367 @default.
- W4308834504 cites W4284989117 @default.
- W4308834504 cites W4295807681 @default.
- W4308834504 doi "https://doi.org/10.1002/art.42391" @default.
- W4308834504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36369798" @default.
- W4308834504 hasPublicationYear "2022" @default.
- W4308834504 type Work @default.
- W4308834504 citedByCount "27" @default.
- W4308834504 countsByYear W43088345042022 @default.
- W4308834504 countsByYear W43088345042023 @default.
- W4308834504 crossrefType "journal-article" @default.
- W4308834504 hasAuthorship W4308834504A5004760940 @default.
- W4308834504 hasAuthorship W4308834504A5008572529 @default.
- W4308834504 hasAuthorship W4308834504A5018812946 @default.
- W4308834504 hasAuthorship W4308834504A5022135220 @default.
- W4308834504 hasAuthorship W4308834504A5023265561 @default.
- W4308834504 hasAuthorship W4308834504A5029793095 @default.
- W4308834504 hasAuthorship W4308834504A5033195023 @default.
- W4308834504 hasAuthorship W4308834504A5034905722 @default.
- W4308834504 hasAuthorship W4308834504A5036855659 @default.
- W4308834504 hasAuthorship W4308834504A5052053321 @default.
- W4308834504 hasAuthorship W4308834504A5052310815 @default.
- W4308834504 hasAuthorship W4308834504A5062998292 @default.
- W4308834504 hasAuthorship W4308834504A5083502971 @default.
- W4308834504 hasBestOaLocation W43088345041 @default.
- W4308834504 hasConcept C126322002 @default.
- W4308834504 hasConcept C142724271 @default.
- W4308834504 hasConcept C159654299 @default.
- W4308834504 hasConcept C168563851 @default.
- W4308834504 hasConcept C197934379 @default.
- W4308834504 hasConcept C203014093 @default.
- W4308834504 hasConcept C203092338 @default.
- W4308834504 hasConcept C204787440 @default.
- W4308834504 hasConcept C27081682 @default.
- W4308834504 hasConcept C2775915377 @default.
- W4308834504 hasConcept C2776912625 @default.
- W4308834504 hasConcept C2778570526 @default.
- W4308834504 hasConcept C2779134260 @default.
- W4308834504 hasConcept C71924100 @default.
- W4308834504 hasConcept C90924648 @default.
- W4308834504 hasConceptScore W4308834504C126322002 @default.
- W4308834504 hasConceptScore W4308834504C142724271 @default.
- W4308834504 hasConceptScore W4308834504C159654299 @default.
- W4308834504 hasConceptScore W4308834504C168563851 @default.
- W4308834504 hasConceptScore W4308834504C197934379 @default.
- W4308834504 hasConceptScore W4308834504C203014093 @default.
- W4308834504 hasConceptScore W4308834504C203092338 @default.
- W4308834504 hasConceptScore W4308834504C204787440 @default.
- W4308834504 hasConceptScore W4308834504C27081682 @default.